Shionogi & Co., LTD., and Maze Therapeutics, Inc. have agreed to develop for market, MZE001, a new substrate reduction therapy drug that could be the first ever pill take orally to treat Pompe disease.

To read more, click here.


An Open Letter to the Pompe Community

On October 28, Amicus Therapeutics issued a press release with an update on the progress of our Pompe program as we received information from the US Food & Drug Administration (FDA) on the regulatory status of our next-generation therapy for the treatment of...

read more

International Survey on Pompe Disease and Covid-19

Over the last 2 years the COVID-19 pandemic has had wide reaching effects on people all over the world. To better understand the impact of the Covid 19 Pandemic on the worldwide Pompe community, the International Pompe Association and the Erasmus MC are undertaking a...

read more

2022 PCMA Pull for Pompe Fundraiser

The AMDA is excited to announce that the 11th Annual PCMA’s Pull for Pompe will take place on Saturday, April 30, 2022 at the National Shooting Complex in San Antonio, Texas! The Pull for Pompe clay shooting event is designed for all ages and ability levels. Please...

read more

 Acid Maltase Deficiency Association


Your generous contribution will go a long way into improving the quality of life of Pompe Disease Patients worldwide. Donations go towards Pompe Disease Research.

If you are interested in learning more about Pompe Disease and would like to make a contribution in support of necessary research, please contact us at:


PO Box 700248

San Antonio, Texas 78270 USA